Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer Trials Australia (CTA) has signed an agreement with India-based Clininvent Research (CRPL) to offer services for Phases I-1V trials to Australian and Indian clients.
Subscribe to our email newsletter
CRPL is a subsidiary of TCG Lifesciences, a provider of drug discovery and development research services company.
CTA CEO Marcus Clark said they expect that this collaboration will be advantageous to their clients as it allows for a seamless transition from a Phase I centre to a network that includes sites in both India and Australia.
"With both CTA and Clininvent collaborating to offer trial design, ethics and governance management, site initiation and monitoring there will be significant efficiencies achieved for client companies," Clark said.